Status:

RECRUITING

Comparison of a Single Versus Double Perclose Technique for TAVR

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions:

Severe Aortic Stenosis

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

Transcatheter aortic valve replacement (TAVR) has become widely recognized as a minimally invasive approach for aortic valve replacement in patients with severe aortic stenosis. It has been proven to ...

Detailed Description

SINGLE-CLOSURE (The utilization of Single versus double perclose devices for transfemoral aortIc valve replacement access site Closure) is an investigator-initiated, open-label, multicenter, randomize...

Eligibility Criteria

Inclusion

  • Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route and a commercially available transcatheter aortic valve; and willingness to comply with protocol specified follow-up evaluations.

Exclusion

  • Principal exclusion criteria were a vascular access site anatomy not suitable for percutaneous vascular closure and the occurrence of vascular access site complications before the TAVR procedure. Additional exclusion criteria were a known allergy or hypersensitivity to any VCD component; unstable active bleeding or bleeding diathesis or significant unman ageable anemia; absence of computed tomographic data of the access site before the procedure; systemic infection or a local infection at or near the access site; life expectancy of \<6 months because of noncardiac conditions; patients who can-not adhere to or complete the investigational protocol for any reason; pregnant or nursing patients; and participation in any other interventional trial.

Key Trial Info

Start Date :

October 20 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 28 2026

Estimated Enrollment :

876 Patients enrolled

Trial Details

Trial ID

NCT06173115

Start Date

October 20 2023

End Date

June 28 2026

Last Update

October 14 2025

Active Locations (25)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (25 locations)

1

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

2

Fujian Provincial Hospital

Fuzhou, Fujian, China

3

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

4

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China